These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 33077514)

  • 41. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TG468: a text graph convolutional network for predicting clinical response to immune checkpoint inhibitor therapy.
    Wang K; Shi J; Tong X; Qu N; Kong X; Ni S; Xing J; Li X; Zheng M
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38390990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival.
    Gao Y; Yang C; He N; Zhao G; Wang J; Yang Y
    Front Oncol; 2020; 10():571545. PubMed ID: 33194669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
    Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
    Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
    Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.
    Huang W; Lin A; Luo P; Liu Y; Xu W; Zhu W; Wei T; Lyu Q; Guo L; Zhang J
    Cancer Gene Ther; 2021 Aug; 28(7-8):864-874. PubMed ID: 32759987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.
    Sha D; Jin Z; Budczies J; Kluck K; Stenzinger A; Sinicrope FA
    Cancer Discov; 2020 Dec; 10(12):1808-1825. PubMed ID: 33139244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
    Stenzinger A; Allen JD; Maas J; Stewart MD; Merino DM; Wempe MM; Dietel M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):578-588. PubMed ID: 30664300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry.
    Jacob A; Wu J; Kolesar J; Durbin E; Mathew A; Arnold S; Chauhan A
    Cancer Med; 2021 Mar; 10(6):2054-2062. PubMed ID: 33619913
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
    Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
    Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
    [No Abstract]   [Full Text] [Related]  

  • 54. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES).
    Yu L; Zhang Y; Wang D; Li L; Zhang R; Li J
    Am J Clin Pathol; 2024 Oct; 162(4):408-419. PubMed ID: 38733635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 56. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy.
    Li X; He Y; Jiang Y; Pan B; Wu J; Zhao X; Huang J; Wang Q; Cheng L; Han J
    Mol Ther Nucleic Acids; 2023 Dec; 34():102026. PubMed ID: 37744173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
    Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
    Front Oncol; 2020; 10():314. PubMed ID: 32232003
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of Three Sequencing Panels Used for the Assessment of Tumor Mutational Burden in NSCLC Reveals Low Comparability.
    Heeke S; Benzaquen J; Hofman V; Long-Mira E; Lespinet V; Bordone O; Marquette CH; Delingette H; Ilié M; Hofman P
    J Thorac Oncol; 2020 Sep; 15(9):1535-1540. PubMed ID: 32450274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.